MedX Health Corp. (
TSX: V.MOL,
OTCQB: MDXHF,
Forum) announced today that it has initiated a joint venture with Onco Tech Llc. Onco Tech is a U.S.-based company with a multi-disciplinary focus on developing and implementing healthcare programs. The joint venture is aimed at marketing MedX’s SIAscopy™ technology for the early detection of skin cancers.
Onco Tech’s focus will be the Mexico, Columbia, and Spain and it will immediately work on obtaining the necessary regulatory clearances for marketing in Mexico and Columbia. MedX already has its CE approval for marketing SIAscopy™ technology in Europe, so no additional approval is required for Spain. Further information can be found
here.
MedX’s corporate mission is to reduce the incidence and mortality rates from melanoma through the use of its technology as an early-detection diagnostic option. The technology has already been rolled-out in Norway, Sweden and the UK and is now being introduced in Canada.
The Company was recently in the news earlier this week when it announced
improved revenues in its Q1 2017 results.
V.MOL
FULL DISCLOSURE: MedX Health Corp is a paid client of Stockhouse Publishing.